Stock Price & Analysis

Based on the analysis of BCRX stock, it is recommended to buy as the stock is near support levels with positive analyst sentiment. However, consider waiting for a bullish confirmation before entering.

BCRX stock is predicted to reach $18 by 2025, driven by strong revenue growth from Orladeyo and positive analyst sentiment. The stock currently trades at $7.37, with a 52-week high of $9.50, indicating upside potential. Analysts maintain a buy rating, citing improved financial guidance and pipeline progress.

The S1 support level for BCRX Stock is $7.54 ,The R1 resistant level for BCRX Stock is $8.06.

As of the end of day on 2025-03-28, the price of BCRX Stock was $7.865.

The target price for BCRX Stock according to analyst rating is 14.73, with the highest price target at 30.00 and the lowest at 8.00. Analysts have a Strong Buy rating on BCRX Stock overall.

The market cap of BCRX is $1.6B.

Analysis and Insights

Valuation Metrics:

BCRX's valuation metrics suggest a mixed outlook. The stock's EV/EBITDA ratio is elevated compared to industry peers, indicating potential overvaluation. However, the price-to-sales ratio is within a reasonable range, reflecting moderate revenue growth expectations.

Technical Analysis:

The stock is currently trading near its 52-week high, with an RSI of 51.69, indicating a neutral position. The MACD is slightly negative, suggesting short-term bearish momentum, while the Fibonacci levels show resistance around $8.04 and support at $7.52.

Analyst Sentiment:

Analysts maintain a Strong Buy consensus with an average price target of $14.73, implying a 74.1% upside. Recent reiterations from JMP Securities and Needham highlight confidence in BCRX's growth prospects.

Recent News Impact:

The resignation of CFO Anthony Doyle in April 2023 has had minimal impact on the stock, as the transition was managed smoothly. This event did not significantly affect investor confidence.

Conclusion:

BCRX may appear overvalued based on its EV/EBITDA ratio, but strong analyst sentiment and growth prospects suggest otherwise. The stock's technical indicators are neutral, and the company's fundamentals remain stable despite management changes.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

BCRX stock is predicted to reach $25 by 2030, driven by strong revenue growth from Orladeyo and a robust pipeline. The company's increased 2025 guidance and expected profitability in 2026 support this bullish outlook. Current analyst targets of $18 suggest this forecast is conservative.

BCRX has a total of 536 employees.